CEPI funds next phase of nanoparticle vaccine platform to support rapid outbreak response

First Word Pharma reported that UB spinout company POP Biotechnologies, co-founded by Jonathan Lovell, has received $9.7 million to continue development of its nanoparticle vaccine platform.